| 1 |
BRAF
| 44件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, FoxO signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Focal adhesion, Natural killer cell mediated cytotoxicity, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Alcoholism, Hepatitis C, Hepatitis B, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Bladder cancer, Chronic myeloid leukemia, Acute myeloid leukemia, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer | D06272
D06272
|
Sorafenib
| 2件: 34 34, 86 |
| 2 |
BRAF
| 44件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, FoxO signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Focal adhesion, Natural killer cell mediated cytotoxicity, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Alcoholism, Hepatitis C, Hepatitis B, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Bladder cancer, Chronic myeloid leukemia, Acute myeloid leukemia, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer | D08524
D08524
|
Sorafenib
| 2件: 34 34, 86 |
| 3 |
BRAF
| 44件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, FoxO signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Focal adhesion, Natural killer cell mediated cytotoxicity, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Alcoholism, Hepatitis C, Hepatitis B, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Bladder cancer, Chronic myeloid leukemia, Acute myeloid leukemia, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer | D10064
D10064
|
Dabrafenib
| 1件: 34 34 |